GlassScriptPhysician profile
Jill D Felder
NPI 1801871587
$16,886.12
in general payments reported to CMS, 2019-2025
62 companies · $2,865 in 2025
The $2,865 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,047 · 2020: $1,540 · 2021: $2,506 · 2022: $2,718 · 2023: $2,687 · 2024: $2,524 · 2025: $2,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,075.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,512.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,070.35 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Xeris Pharmaceuticals, INC. | $1,343.40 | 2020-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,317.19 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $1,159.72 | 2019-2025 | Korlym |
| Amgen INC. | $1,018.70 | 2019-2025 | Repatha, Repatha, Evenity |
| Recordati_rare_diseases_inc. | $961.74 | 2021-2025 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $660.73 | 2019-2023 | Verquvo, Steglatro, Segluromet |
| Abbott Laboratories | $485.93 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Mannkind Corporation | $482.22 | 2022-2024 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $448.57 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $443.04 | 2019-2025 | |
| Amarin Pharma, INC. | $420.63 | 2019-2023 | |
| Zealand Pharma US, INC. | $323.95 | 2020-2022 | |
| Antares Pharma, INC. | $252.31 | 2019-2025 | Xyosted, Tlando, Nocdurna |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Felder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.